The rationale of using metyrapone in subjects affected by ACTH-independent hypercortisolism is that, in these patients, the compensatory rise of ACTH secretion during treatment should not be observed, since ACTH is chronically suppressed by the autonomous cortisol secretion. Here, POMC is linked to adrenal gland hyperfunction.